Vertaling van "al a new risk scheme " (Nederlands → Frans) :

Bespreking van: Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage.
Analyse de: Fang MC, Go AS, Chang Y et al. A new risk scheme to

new risk scheme to predict warfarinassociated hemorrhage.
new risk scheme to predict warfarin-associated hemorrhage.

Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Olesen JB, Lip GYH, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.

Olesen JB, Lip GYH, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.
Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.

voor de financiering van geneesmiddelen, de zogenaamde “risk sharing schemes”.
Ces dernières années, plusieurs pays ont utilisé une nouvelle approche pour le financement des médicaments, appelée “risk sharing schemes”.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Reinforcing its efficacy and safety profile, new long-term data from a pivotal fracture trial show Aclasta preserved bone mass in patients who received annual infusions for six years and the risk of new morphometric spine fractures was reduced by 52% when measured as a secondary endpoint compared to those who stopped treatment at three years.
Renforçant son profil d’efficacité et d’innocuité, de nouveaux résultats provenant d’un essai pivot de long terme sur les fractures montrent que Reclast/Aclasta conserve la masse osseuse de malades qui ont reçu une perfusion annuelle pendant six ans. En outre, le risque de nouvelles fractures morphométriques de la colonne vertébrale, mesuré en tant que critère secondaire, a été réduit de 52% par rapport aux malades qui ont arrêté le traitement au bout de trois ans.

Consistent with this focused research strategy, new Phase II data demonstrates that ACZ885, currently marketed as Ilaris for the rare disease cryopyrin-associated periodic syndrome (CAPS), provided highly statistically significant risk reduction of acute flares in gout patients compared to the anti-inflammatory standard of care.
Cette approche stratégique est illustrée par ACZ885, un médicament actuellement commercialisé sous la marque Ilaris pour traiter le syndrome périodique associé à la cryopirine (CAPS), une maladie rare. De nouveaux résultats d’une étude de phase II ont montré que ce médicament induisait une réduction importante, hautement significative sur le plan statistique, du risque de crises aiguës de goutte par comparaison avec le traitement anti-inflammatoire standard.

Submission for US approval of Diovan (valsartan) for the prevention of new onset diabetes in hypertensive patients with impaired glucose tolerance and increased cardiovascular risk was achieved in July.
médicament qui prévient l’apparition du diabète et une hausse des risques cardiovasculaires chez les patients présentant une tolérance au glucose diminuée.

We assess the potential effects of our operations on the environment – and the health and safety of our associates and neighbors – to ensure that the benefits of new products, processes and technologies outweigh any risks.
Nous évaluons toujours les effets possibles de nos activités sur l’environnement – de même que sur la santé et la sécurité de nos collaboratrices et collaborateurs et de ceux qui nous entourent – afin de nous assurer que les bénéfices de nouveaux produits, de nouveaux procédés ou de nouvelles technologies sont supérieurs aux risques potentiels.